Miguel A. Villalona-Calero, MD, The James Comprehensive Cancer Center at Ohio State

Dr. Villalona-Calero is a medical oncologist, lung cancer specialist, and an expert in drug development at the Ohio State University (OSU) Comprehensive Cancer Center. Dr. Villalona-Calero’s current academic appointments are professor of the Departments of Internal Medicine and Pharmacology of The Ohio State University College of Medicine and Public Health. He is also the director of the Solid Tumor Experimental Therapeutics program for OSU Comprehensive Cancer Center and co-medical director of the Clinical Research Unit at the Arthur James Cancer Hospital.
Dr. Villalona-Calero received his medical degree (magna cum laude) from Universidad Nacional Pedro Henríquez Urena (U.N.P.H.U.), in Santo Domingo, Dominican Republic. He completed his internship and residency at the State University of New York Health Sciences Center, and Medical Oncology fellowships at the University of Minnesota Hospital & Clinics and Roswell Park Cancer Institute. He was further trained in the drug development field in the Institute for Drug Development, University of Texas Health Sciences Center and in Health Policy Leadership from New York University.
Dr. Villalona’s most significant contribution is translating his and others laboratory observations into cancer therapy. His unique education background combining medicine, oncology, drug development, pharmacology and health policy leadership, as well as his devotion and compassion to advocate cancer and take care of cancer patients, make Dr. Villalona-Calero a true bench to bedside translational researcher.
Recognition of his work by his peers has led to more than 70 peer-reviewed publications in journals with moderate to high impact factor, 150 abstracts, membership in three journal editorial boards, three NCI-supported R21 grants, a V Foundation/AACR Translational Cancer Research Award, an N01 clinical trials contract with the NCI (all as principal investigator), two ARRA supplements from the NCI, and numerous investigator-initiated clinical trials with pharmaceutical companies support. His abilities as reviewer and mentor has led to membership or faculty status in study sections (NCI/C-ONC, ASCO/AACR Vail Workshop in Clinical Research, NCI Investigational Drug Steering Committee, AACR 2009 annual meeting co-chair), as well as, primary mentor in two K awards and faculty in two T-32s and a K-12 grant. Respond and Donate

Leave a Reply